Gilead Sciences Inc. (NASDAQ:GILD) Deals with its HCV Drug Issue

Gilead Sciences Inc. (NASDAQ:GILD) Deals with its HCV Drug Issue Gilead Sciences Inc. (NASDAQ:GILD) has taken the decision to limit the number of patients it admits to its support path patient assistance program. The decision only affects those patients seeking … Continue reading

Gilead Sciences: Still Plenty of Growth Despite 'Stagnated' HepatitisC

Gilead Sciences: Still Plenty of Growth Despite 'Stagnated' Hepatitis–C For Gilead, the company's HCV launch in the U.S. has stagnated but there is still plenty of opportunity for ex-U.S. growth. As payors still won't let HCV patients flow through the … Continue reading

Gilead Sciences, Inc. (GILD) Leads The HCV Race Despite Competition From

Gilead Sciences, Inc. (GILD) Leads The HCV Race Despite Competition From … AbbVie launched its hepatitis C drug, Viekira Pak, with the intent to cannibalize Gilead's hepatitis C drug sales, as evident from the fact that the company immediately went … Continue reading

Gilead Experiencing Bumpy Ride Despite Strong Fundamentals

Gilead Experiencing Bumpy Ride Despite Strong Fundamentals In December 2013, Gilead launched Sovaldi, a medicine to treat hepatitis C, and its sales boosted revenues for the calendar year 2014 which were around $ 10.3 billion. In October 2014, the company … Continue reading